BACKGROUND: Oral paliperidone and lurasidone are new second-generation antipsychotics (SGAs). Empirical evidence on the comparative costs and persistence of these 2 agents are absent in the literature.
S chizophrenia is a severe chronic mental disorder with a substantial economic burden in the United States. Estimated to affect approximately 1% of the U.S. population, schizophrenia costs amounted to $62.7 billion in the United States in 2002, 36% of which was direct medical costs. [1] [2] [3] With their availability, antipsychotic medications became the cornerstone of treatments for schizophrenia more than half a century ago. 4 Since 1989, a variety of second-generation antipsychotics (SGAs) have been developed, and SGAs are now recommended as the first-line therapy for schizophrenia owing to their better safety profile compared with first-generation antipsychotics. [5] [6] [7] SGAs have been reported to dominate the U.S. antipsychotics market with a market share of 86% in 2008. 8 Consequently, the frequent usage of SGAs leads to greater economic burden on public and private health care payers because SGAs are considerably more expensive than first-generation antipsychotics. [8] [9] [10] [11] Moreover, costs and outcomes associated with drug treatments vary across different types of SGAs. 9, [12] [13] [14] Given the rapidly increasing per capita use of SGAs among schizophrenia patients in the United States and increasing concerns over health care budget, it is meaningful to not only look at the efficacy and safety of these drugs but also to consider the associated costs. 8, 15, 16 Ample evidence exists regarding costs and health care use associated with several previously marketed SGAs, including olanzapine, risperidone, quetiapine, aripiprazole, and ziprasidone. 9, 10, 12, 13, 15, 17 Nevertheless, 2 new oral SGAs, paliperidone and lurasidone, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in recent years; however, empirical evidence on costs and health care resource utilization for the use of these 2 medications is still absent in the literature. 18, 19 Paliperidone was introduced in
• Second-generation antipsychotics (SGAs) are widely used for schizophrenia treatment. The access fees of oral paliperidone and lurasidone are higher than the previously marketed SGAs.
• Currently, there is no retrospective empirical evidence on the comparative effectiveness and costs of oral paliperidone and lurasidone in schizophrenia treatment in the literature.
What is already known about this subject
• This study generated real-world evidence regarding health care use, costs, and persistence associated with oral paliperidone and lurasidone in comparison with olanzapine, risperidone, quetiapine, and aripiprazole.
• Clinical information was provided to support choices between 2 new second-generation antipsychotics and several old secondgeneration antipsychotics from the perspective of clinicians and health care payers.
What this study adds
Schizophrenia patients (ICD-9-CM code 295.xx) with a claim of the study medications (oral paliperidone, lurasidone, aripiprazole, quetiapine, risperidone, and olanzapine) were identified and selected. The first fill date was defined as the index date. In addition, the eligible cohort for analysis was restricted to patients who met the following criteria: (a) aged > 18 years on the index date; (b) did not use an SGA during the 180 days prior to the index date; and (c) were continuously enrolled for at least 360 days post-index. A longer pre-index period was not used (i.e., 360 days) because a substantial portion (39.75%) of samples would be lost. Also, a 180-day pre-index period has been frequently used in studies on antipsychotics. 9, 12, [23] [24] [25] 
Measures
This study used an intent-to-treat approach, and the outcome measures consisted of all-cause medical and pharmacy costs, SGA treatment persistence, and events including hospitalization and emergency department (ED) visits over the 360-day follow-up period. Costs outcomes included total costs, medical services costs, drug costs, hospitalization costs, outpatient costs, and ED costs. All-cause costs based on the total amount paid by insurers and patients were used in this study. Moreover, costs were adjusted to 2013 U.S. dollars using the medical care component of the Consumer Price Index. 26 In addition, we examined the number of hospitalizations and the number of ED visits as outcomes. Finally, persistence was operationalized by the episode duration (time-to-discontinuation). This was defined as the number of days since index date until a 15-day or longer gap between 2 fills (the end of supply of a fill and the fill date of the next fill) for the same drug. 12, 21, 27 The episode duration was right censored to be as long as the 360-day follow-up period.
In the current study, demographic variables and health information in the pre-index period were used as baseline characteristics. Specifically, the baseline characteristics included the following: (a) demographic variables, which included age, sex, race (white vs. nonwhite), and insurance type (Medicare vs. commercial); (b) costs, which included total costs, medical services costs, drug costs, hospital costs, outpatient costs, and ED costs; (c) the number of pre-index hospitalizations and the number of pre-index ED visits; and (d) Charlson Comorbidity Index (CCI) scores. These variables were used in descriptive comparisons of baseline characteristics.
In multivariate analyses, all the aforementioned baseline characteristics except the pre-index cost variables were included. An exception is pre-index total costs, which were the only type of costs included in regressions as an explanatory variable. We also used additional information in the pre-index period representing health services use, comorbid conditions, and use of other medications. Specifically, these variables included (a) additional resource utilization-the number of outpatient visits and the number of psychiatric facility visits/ December 2006; lurasidone was introduced in October 2010; and both were approved for the treatment of schizophrenia. 18, 19 Lurasidone was also approved for the treatment of bipolar disorder by the FDA in July 2013. 20 New drugs are likely to incur high medication access fees. 8 Therefore, it is important to investigate the overall impact of these new oral antipsychotics on health services use. In addition to costs, empirical evidence regarding persistence associated with oral paliperidone and lurasidone in real-world practice is not documented in the literature. This evidence gap needs to be filled given that persistence is an important measure of antipsychotic drug therapy effectiveness. 21, 22 The primary objective of this retrospective analysis of administrative claims databases was to assess health care use and costs associated with oral paliperidone and lurasidone in relation to SGAs previously introduced into the market, including olanzapine, risperidone, quetiapine, and aripiprazole. In addition, treatment persistence of SGA users was evaluated. We restricted our evaluation of new antipsychotics to oral paliperidone and lurasidone because we could not collect enough use samples for other new antipsychotics (e.g., asenapine and iloperidone). To an extent, these covariates reflected individual information, comorbid conditions, and disease severity among patients with psychosis. 10, 29, 30 Data Analysis All analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, NC) and Stata version 12 (Stata Corp, College Station, TX) statistical software. Significance level was set at P < 0.05. Descriptive statistics were obtained for baseline characteristics and outcome variables, including frequency distributions for categorical variables and means and standard deviations (SDs) for continuous variables. Chi-square tests and analysis of variance (ANOVA) were used to compare the patients across the drug groups. Additionally, costs were described using medians and interquartile ranges (IQRs), and compared using Kruskal-Wallis tests.
■■
Multivariate regression analyses were conducted to evaluate the utilization and persistence associated with paliperidone and lurasidone use. In the regressions, an indicator variable was included for each of the study medications, and aripiprazole was used as the left-out dummy variable because aripiprazole has relatively less severe side effects compared with other commonly used SGAs and is increasingly gaining popularity. 8, 31 Ordinary least squares (OLS) regressions were used for costs, and a censored regression model was used for episode duration in order to take into consideration the right-censoring. 32, 33 Poisson regressions were used for number of events outcomes. We reported the marginal effects at means instead of the coefficients from Poisson regressions results.
Sensitivity analyses were carried out to examine the robustness of the results from base-case analyses to skewed or zero mass distributions of some outcomes. We performed generalized linear model (GLM) regressions defined by a logarithmic link function with a gamma distribution for total costs, medical services costs, drug costs, and outpatient costs. This specification is widely used in modeling health care costs with skewed distributions. 9, 16, 24, [34] [35] [36] [37] [38] Next, logistic-GLM two-part models (TPMs) were used for analyses of hospital costs and ED costs, since 58.59% of the patients in the sample had no hospital costs, and 46.62% of the patients had no ED costs. There 
TABLE 1

Baseline Characteristics of Schizophrenia Patients in Study Sample
were 2 processes in the TPMs. 32, 39 First, a logistic regression was performed to estimate the probability of having nonzero costs. Then, a GLM regression modeled the costs among the samples that had costs. The probability of having any costs and the expected costs conditional on having any costs were multiplied to calculate the expected costs, and marginal effects were calculated accordingly. 39 By the same token, the number of hospitalizations and the number of ED visits were analyzed using Hurdle models. 32, [39] [40] [41] Hurdle models differ from TPMs in that the second step models are truncated Poisson regressions instead of GLMs. 32, 41 Marginal effects at means for TPM, GLM, and Hurdle model estimates are reported as results. Standard errors of marginal effects were obtained using delta method in GLMs and TPMs and using bootstrapping in Hurdle models. 39, 42 Additionally, instrumental variable (IV) models were applied to address potential bias caused by endogeneity of treatment. When the baseline characteristics were examined (Table 1) , it was evident that lurasidone users had great differences in characteristics from patients in other drug groups. Although unbalanced observable characteristics do not necessarily imply omitted variable bias, we considered it meaningful to test whether omitted variable bias existed. To that end, IV models were implemented. Six IVs were selected for the current analysis. The first IV was the diffusion rate of lurasidone on the 3-digit ZIP code level (the number of lurasidone prescriptions divided by the number of total antipsychotics prescriptions aggregated by the 3-digit ZIP code). The second IV was the fraction of aripiprazole prescriptions of a given provider. The first 2 IVs are preference-based IVs. 43 Furthermore, during the period encompassed by the databases (January 2007-July 2013), generic forms of several SGAs (e.g., risperidone, September 15, 2008; olanzapine, October 24, 2011; ziprasidone, March 2, 2012; and quetiapine, March 27, 2012) became available in the United States. 44 In light of that, 4 IVs were created, and each of them indicated whether each of these drugs had generic forms in the market on the index day. The 4 generic form availability indicators were created to exploit differential spillover effects. 45, 46 OLS regressions (naïve regressions) were also run for all outcomes using the subsample. Please see Appendices C-E (available in online article) for more details on the implementation, tests, and discussion of IVs.
■■ Results Baseline Characteristics
A total of 15,603 schizophrenia patients (Figure 1 ) who initiated SGA therapy with 1 of the study medications were identified. Of these patients, 264 (1.7%) were oral paliperidone users; 182 (1.2%) were lurasidone users; 2,583 (16.6%) were aripiprazole users; 4,741 (30.4%) were quetiapine users; 5,351 (34.3%) were risperidone users; and 2,482 (15.9%) were olanzapine users. Baseline characteristics are summarized in Table 1 . All characteristics were significantly different across drug groups. In particular, lurasidone users had much lower pre-index costs of any types except drug costs. In addition, they had fewer hospital admissions (mean [SD] = 0.57 [2.22] Table 2 presents the descriptive statistics of outcomes in the follow-up period. All outcomes were statistically significantly different across the 6 drug groups. In particular, lurasidone users had much lower costs of any types except drug costs and much fewer events of any types when compared with other groups. Also, the mean and median drug costs of paliperidone users ($6,123 
Unadjusted Analysis
Multivariate Analysis
Base-case multivariate analysis results are shown in Table 3 . The OLS results of costs suggested that paliperidone was not associated with significantly different costs of any type from aripiprazole. In contrast, lurasidone was associated with significantly lower total costs (−$7,052; 95% confidence interval Table 4 lists the results of the GLM, TPM, and hurdle models. Overall, the GLM and TPM estimates are in line with the OLS results. In particular, all GLM and TPM estimates have the same directions and significance implications as the corresponding OLS estimates. However, the GLM and TPM estimates have greater standard errors and therefore wider CIs than OLS estimates. In a few cases, GLM and TPM produced greater values of point estimates than OLS. In the hurdle models, only lurasidone and quetiapine significantly associated with the number of hospitalizations and the number of ED visits. The hurdle model estimates of other drugs have the same direction as the corresponding Poisson estimates. In fact, the hurdle model estimates also have similar values, yet they are no longer statistically significant. This change is also likely attributable to the inflated standard errors.
Results of IV regressions are displayed in Table 5 . According to the Hausman tests results, estimates from the naïve regressions and the IV regressions are not systematically different for any of the outcomes. As such, we discuss the base-case analyses results in what follows.
■■ Discussion
This retrospective cohort study compared health care use and treatment persistence for schizophrenia patients who used oral paliperidone or lurasidone versus those who used 47 It is documented in the literature that high out-of-pocket drug costs can lead to suboptimal persistence and high overall costs. 48 If the first possibility is true, then the results of the this study-that lurasidone is associated with lower total health costs-should raise some awareness about increasing the persistence associated with lurasidone by designing a cost-sharing strategy that reduces perceived costs by patients. Current clinical evidence does not support the second and the third possibilities. 19, 49 However, if they are indeed true, then the long-term consequences of using lurasidone need more investigation. Future studies can focus on examining the factors related to the persistence associated with lurasidone.
New antipsychotics are likely associated with high access fees. Hence, evidence on whether the new antipsychotics can reduce health care use in other aspects or generate superior effectiveness is important to making choices between various drugs. It is reported in the literature that oral paliperidone has similar efficacy and safety profiles as risperidone, its parent compound. 50 This study suggests that oral paliperidone has a similar association with health care use as risperidone. However, oral paliperidone is associated with poorer persistence than risperidone. The findings of the current study do not favor the prescription of oral paliperidone when risperidone is available. Lurasidone is considered to have a better safety profile than several other SGAs, including olanzapine and quetiapine. 19 This study suggests that while lurasidone is associated with lower costs and fewer hospitalizations and ED visits than other SGAs, it is also associated with a lower level aripiprazole, quetiapine, risperidone, or olanzapine. Oral paliperidone and lurasidone are 2 relatively new oral SGAs. To our knowledge, this is the first empirical study to assess health care use and persistence associated with these 2 medications in the U.S. setting.
Several key findings resulted from this study. Oral paliperidone is not associated with cost savings when compared with aripiprazole or olanzapine, although it is associated with reduced costs of all types except drug costs when compared with quetiapine. Also, oral paliperidone incurs higher drug costs than risperidone and lower drug costs than olanzapine, while the effects of these 3 drugs on other types of costs are statistically similar to each other. In contrast to oral paliperidone, lurasidone is less costly when compared with any of the other study medications. In fact, this conclusion applies to all types of costs except drug costs on which risperidone has similar cost-saving effects as lurasidone. Additionally, lurasidone users have fewer hospitalizations and ED visits when compared with any other studied SGAs. Oral paliperidone is related to moderately reduced number of hospitalizations compared with quetiapine and moderately reduced number of ED visits when compared with aripiprazole and quetiapine.
Another finding is that paliperidone and lurasidone are associated with poorer persistence than the 4 other SGAs. This is worth concern because persistence can usually impact long-term outcomes. It also highlights the importance of investigating the drugs in a time frame beyond 12 months after initiation. If lurasidone is associated with poorer persistence than the other drugs in the long run, its cost-saving effects may not persist. The poor persistence could be a result of high drug 
TABLE 4
Estimates of Costs, Hospitalization, and ED Visits Associated with SGAs from Sensitivity Analyses of persistence. Several existing reviews and guidelines do not recommend lurasidone over less expensive SGAs as the first choice of antipsychotic drugs because of price concerns. 49, 51, 52 Our findings necessitate a reconsideration of the impression that lurasidone should not be used as first-line therapy in the presence of other SGAs because of its higher access fees. 49 In fact, using lurasidone first and then switching to other SGAs in the case of no response or intolerance should also be a feasible strategy as far as the overall costs are concerned. Future study should focus on testing whether this strategy is clinically warranted.
This study utilized recent administrative claims databases (January 2007-June 2013). A moderately large group of patients who used 1 of the study medications and had no prior use of SGAs were identified. Using such an initiator approach avoided complicated overlapping episodes issues that are often encountered in multi-episode approaches. 17 Persistence is an important measure of effectiveness of SGAs. 9, 21, 53 Including persistence as an outcome in the current study allowed the evaluation to incorporate not only the costs but also an aspect of clinical effectiveness. Moreover, GLM, TPM, and hurdle model regressions were used to take into account skewed and zero mass distributions of costs. Furthermore, IV regressions and Hausman tests were used to detect and correct omitted variable bias. Finally, results are robust across various analytic strategies, and there is no evidence of omitted variable bias.
Limitations
There are limitations to this study. First, although the total sample size is large, the population of paliperidone users and lurasidone users are modest compared with the other groups. Second, claims data do not normally capture important information such as disease severity and clinical symptoms. Although a long list of variables were controlled in the regressions and the IV models were used as an alternative method, potential bias due to unmeasured covariates could not be ruled out entirely. Third, using the initiator approach may restrict the generalizability of this study because subsequent episodes of patients in the sample and patients who had pre-index exposure to SGAs were not included in the analyses. Fourth, the pre-index period was only 180 days, which may fail to capture some chronic conditions of patients. Only outcomes in a 360-day post-index period were analyzed; therefore, longerterm impacts of the study medications on outcomes are not available. Finally, the data source did not include information on beneficiaries of Medicaid, which is the largest payer for schizophrenia in the United States. 16 Medicaid programs in some states require prior authorization but also require very low copayments (e.g., $1 in Kentucky and $3 in Indiana). 54, 55 Consequently, drugs may have different cost patterns in Medicaid programs, so the results from the this study may not be generalizable to a population that includes Medicaid beneficiaries.
■■ Conclusions
In this study population, oral paliperidone was not associated with lower health care use as compared with other SGAs. Lurasidone was associated with lower health care use as compared with other commonly used SGAs. Patients were observed to be less persistent with oral paliperidone and 
APPENDIX B ICD-9-CM Diagnosis Codes for Other Used Diagnoses
Instrumental variable (IV) models can test whether omitted variable bias exists, remove bias caused by treatment selectivity, and recover the unbiased estimates of treatment effects. [1] [2] [3] However, IV models with multiple treatments are complicated and difficult to implement. 4 As such, we used a subsample comprised only of aripiprazole and lurasidone users so that it would be possible to carry out IV models with a two-level-treatment variable. Moreover, IV models are best interpreted in linear equations. 5, 6 Therefore, linear IV models were used irrespective of the nature of outcomes. Six IVs were selected for the current analysis. The first IV was the diffusion rate of lurasidone on the 3-digit ZIP code level (the number of lurasidone prescriptions divided by the number of total antipsychotics prescriptions aggregated by the 3-digit ZIP code). The second IV was the fraction of aripiprazole prescriptions of a given provider. The 3-digit ZIP code level diffusion rate of aripiprazole and the fraction of lurasidone prescriptions of a given provider were not used because they either had perfect collinearity with the other variables or could not significantly predict the treatment. The first 2 IVs are preference-based IVs, and both have been broadly used in previous studies in the literature .2,6-18 Finally, 4 IVs were created to indicate whether each of risperidone, olanzapine, ziprasidone, and quetiapine had generic forms in the market on the index day. Between-drug spillover effects as a result of patent expiration are a widely reported phenomenon in the drug market. 19, 20 Such effects cause the amount of utilization of other drugs in the same therapeutic class to change. 20 As a matter of fact, there could be differential spillover effects on other drugs. 20 The 4 generic-form availability indicators were created to exploit differential spillover effects. 19, 20 Ordinary least squares (OLS) regressions (naïve regressions) were run for all outcomes using the subsample along with the IV regressions, and Hausman tests were performed to identify the significance of treatment selectivity. 1 In Hausman tests, if naïve regressions and IV regressions results do not differ systematically, then it indicates that there is no treatment selectivity between aripiprazole and lurasidone, 1 and base-case analyses should provide reliable results. Because of their nature, the generic-form indicators should be strictly exogenous to treatment assignment. Furthermore, they should not impact the outcomes directly because they are not study medications in the subsample. However, the first 2 IVs do not necessarily hold such properties as strongly as the last 4 IVs. Thus, the first 2 IVs were regressed on patient characteristics as an indirect test of the exogeneity assumption of these IVs. Overidentification tests (Sargan statistics) were applied to results of all IV models as an alternative test of joint exogeneity of all IVs. 21, 22 However, overidentification tests were not used as golden standards in the current study because they are often regarded to have little value in applied work. 21 By and large, the naïve OLS regression results and the IV regression results are not contradictory to each other. This is reflected by the Hausman test results described in the main text of this study. The first-stage F-statistic was 317.90, and all IVs were significant predictors of treatment. Of the 13 variables used in the indirect test of exogeneity of the 2 preference-based IVs, 3 were significantly associated with the 3-digit ZIP-code level diffusion rate of lurasidone, and 1 was significantly associated with the fraction of aripiprazole prescriptions of a given provider (see Appendix D). Of the 11 IV regressions, IVs were not jointly exogenous in 4 regressions according to results of the Sargan statistics tests (see Appendix E). On the whole, all the IVs used were valid. Altogether, there is no strong evidence of omitted variable bias in the naïve regressions.
We did not carry out a propensity score matching (PSM) procedure to address bias for several reasons. First, there is no established matching method for multigroup comparisons. 23 Second, using PSM in a subsample containing users of 2 drugs may lead to a very small sample size for analysis and dramatically increase chances of type 2 errors. Last, PSM only strengthens balance on observed characteristics and does nothing to balance unobserved characteristics. In fact, the forced balance on measured covariates in PSM may even exacerbate imbalance on unmeasured covariates. 
